AstraZeneca: SBLA For Enhertu, Pertuzumab Combination Granted Priority Review In The US
(RTTNews) - AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application for Enhertu in combination with pertuzumab has been accepted and granted Priority Review in the US for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. The sBLA is based on data from the DESTINY-Breast09 Phase III trial. The FDA action date for their regulatory decision, is anticipated during the first quarter of 2026.
The sBLA is being reviewed under the Real-Time Oncology Review programme. RTOR allows the FDA to review components of an application before submission of the complete application.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.